Cidara Therapeutics Inc (NASDAQ: CDTX) is 325.42% higher on its value in year-to-date trading and has touched a low of $10.14 and a high of $56.83 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CDTX stock was last observed hovering at around $49.33 in the last trading session, with the day’s gains setting it 334.4%.
Currently trading at $383.73K, the stock is 70.45% and 97.63% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.94 million and changing 1936162% at the moment leaves the stock 143.45% off its SMA200. CDTX registered 78.68% gain for a year compared to 6-month gain of 106.85%. The firm has a 50-day simple moving average (SMA 50) of $24.3027 and a 200-day simple moving average (SMA200) of $19.729.
The stock witnessed a 100.13% loss in the last 1 month and extending the period to 3 months gives it a 130.58%, and is 125.39% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 16.92% over the week and 9.29% over the month.
Cidara Therapeutics Inc (CDTX) has around 38 employees, a market worth around $622.94M and $0.30M in sales. Profit margin for the company is -59994.04%. Distance from 52-week low is 373.67% and -15.48% from its 52-week high. The company has generated returns on investments over the last 12 months (-126.77%).
The EPS is expected to grow by 71.38% this year, but quarterly earnings will post -100.00% year-over-year. Quarterly sales are estimated to shrink -100.00% in year-over-year returns.
58.0 institutions hold shares in Cidara Therapeutics Inc (CDTX), with institutional investors hold 87.73% of the company’s shares. The shares outstanding are 12.21M, and float is at 7.67M with Short Float at 8.45%. Institutions hold 86.20% of the Float.
The top institutional shareholder in the company is MONASHEE INVESTMENT MANAGEMENT LLC with over 0.37 million shares valued at $4.41 million. The investor’s holdings represent 8.0876 of the CDTX Shares outstanding. As of 2024-06-30, the second largest holder is BVF INC/IL with 0.34 million shares valued at $4.1 million to account for 7.5169 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 0.18 million shares representing 3.9558 and valued at over $2.16 million, while CHECKPOINT CAPITAL L.P. holds 3.1863 of the shares totaling 0.15 million with a market value of $1.74 million.
Cidara Therapeutics Inc (CDTX) Insider Activity
The most recent transaction is an insider purchase by Mineo Chrysa, the company’s Director. SEC filings show that Mineo Chrysa bought 2,270 shares of the company’s common stock on Jun 02 ’25 at a price of $21.71 per share for a total of $49281.0. Following the purchase, the insider now owns 2270.0 shares.
Cidara Therapeutics Inc disclosed in a document filed with the SEC on Jun 03 ’25 that Mineo Chrysa (Director) bought a total of 1,050 shares of the company’s common stock. The trade occurred on Jun 03 ’25 and was made at $23.44 per share for $24614.0. Following the transaction, the insider now directly holds 3320.0 shares of the CDTX stock.
Still, SEC filings show that on Mar 11 ’25, Ward Shane (COO & CLO) disposed off 1,664 shares at an average price of $21.96 for $36542.0. The insider now directly holds 14,674 shares of Cidara Therapeutics Inc (CDTX).
